AroCell AB: New application for AroCell TK 210 ELISA opens new opportunities for drug development research
September 18 2017 - 8:15AM
Uppsala September 18,
2017
PRESS RELEASE
New application for AroCell TK
210 ELISA opens new opportunities for drug development
research
AroCell AB (publ) announces today that an abstract submitted by
Kiran Kumar Jagarlamudi et al entitled "Doxorubicin effects on
leukemia and breast cancer cells in culture on the TK1 protein
levels using AroCell TK 210 ELISA: a tool for drug development" was
accepted by the Purine and Pyrimidine Society for presentation at
their annual meeting in Gdansk, Poland, September 20-24,
2017.
The purpose of this study was to evaluate the
capacity of AroCell TK 210 ELISA to measure TK1 protein levels in
cultured tumor cell lines. The effects of Doxorubicin on TK1
protein levels in extracts and media from CEM lymphoblastic cells
as well as MDA-MB breast cancer cell cultures were studied for 24
hours. The results demonstrated that changes in intracellular and
extracellular TK1 protein levels at different concentrations of DOX
provide information about induction of TK1 in the cells, probably
related to DNA damage, as well as release of TK1 protein into the
media due to cytotoxicity.
"The results are very promising and demonstrate
that AroCell TK 210 ELISA can be used to determine TK1 as a
biomarker in in-vitro cell culture studies with drugs targeting
cell proliferation and DNA repair. This means that our TK 210 ELISA
test also has the potential to enable routine application in drug
development studies" says Jan Stålemark AroCell CEO.
For additional
information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com
This information is information
that AroCell is obliged to make public pursuant to the EU Market
Abuse Regulation and the Securities Markets Act. The information
was submitted for publication, through Jan Stålemark, at 14.15 CET
on 18 September 2017.
About AroCell
AroCell AB (AROC) is a Swedish company that
develops standardized modern blood tests to support the prognosis
and follow up of cancer patients. AroCell's new technology is based
on patented methods to measure TK1 protein levels, which provide
valuable information about the rate of cell turnover. A tumor has
high cell turnover (rate of cell division and cell death) and as a
result TK1 can be detected in the blood with a simple laboratory
test, called TK 210 ELISA. The test provides valuable clinical
information for prognosis and optimization of treatment strategies.
The test may also be used for monitoring disease relapse. AroCell
(AROC) is listed at Nasdaq First North and has about 2,500
shareholders. For more information, please see www.arocell.com.
Redeye AB is AroCell:s Certified Adviser.
AroCell press release Sept 18,
2017
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: AroCell AB via Globenewswire
Archrock (NYSE:AROC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Archrock (NYSE:AROC)
Historical Stock Chart
From Apr 2023 to Apr 2024